How England Is Undermining Clinical Research
This article was originally published in Scrip
Executive Summary
Authorities in England are viewing life-extending medicines as "simple commodities like groceries", says Wim Souverijns, general manager of Celgene UK & Ireland. Without a change in attitude, and if plans for a new Cancer Drugs Fund go ahead, companies could decide to relocate their studies from England, although plans for devolution could provide a chink of light for companies, says Souverijns.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.